Harmony Biosciences (HRMY) Tops Q2 EPS by 20c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts HRMY Hot Sheet
Join SI Premium – FREE
Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $0.92, $0.20 better than the analyst estimate of $0.72. Revenue for the quarter came in at $200.5 million versus the consensus estimate of $204.59 million.
GUIDANCE:
Harmony Biosciences sees FY2025 revenue of $820-860 million, versus the consensus of $843.6 million.
For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
- Therma Bright plans $420,000 non-brokered private placement
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
